• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

下调 U2AF1 促进 ARV7 剪接和前列腺癌进展。

Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression.

机构信息

Surgical Department I (Urology Department), Longhua Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.

Surgical Department I (Urology Department), Longhua Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai, 200032, China.

出版信息

Biochem Biophys Res Commun. 2021 Feb 19;541:56-62. doi: 10.1016/j.bbrc.2020.12.111. Epub 2021 Jan 19.

DOI:10.1016/j.bbrc.2020.12.111
PMID:33477033
Abstract

The present study aims to investigate the roles of U2 Small Nuclear RNA Auxiliary Factor 1 (U2AF1) in the resistance to anti-androgen treatment in prostate cancer and its underlying mechanism. U2AF1 and androgen receptor variant 7 (ARV7) knockdown and overexpression were introduced in PC3 and DU145 cells. In addition, a bicalutamide-resistant PC3 (PC3 BR) cell line was also constructed. Cell count, MTT and soft agar colony formation assays were performed to evaluate cell proliferation. qRT-PCR was applied to determine the mRNA levels of U2AF1, ARV7 and Mitogen-Activated Protein Kinase 1 (MAPK1). Western blot was used to determine the MAPK1 protein expression. A negative correlation between ARV7 and U2AF1 in prostate tumor tissues was observed. U2AF1 downregulation was correlated with poor prognosis in prostate cancer patients. U2AF1 exhibited a negative correlation with ARV7 and its downregulation promoted prostate cancer cell proliferation and bicalutamide resistance. The regulatory effects of U2AF1 on ARV7 splicing were associated with MAPK1. U2AF1 affected prostate cancer proliferation and anti-androgen resistance by regulating ARV7 splicing.

摘要

本研究旨在探讨 U2 小核 RNA 辅助因子 1(U2AF1)在前列腺癌对抗雄激素治疗耐药中的作用及其潜在机制。在 PC3 和 DU145 细胞中敲低和过表达 U2AF1 和雄激素受体变体 7(ARV7),并构建了比卡鲁胺耐药 PC3(PC3 BR)细胞系。通过细胞计数、MTT 和软琼脂集落形成实验评估细胞增殖。qRT-PCR 用于测定 U2AF1、ARV7 和丝裂原活化蛋白激酶 1(MAPK1)的 mRNA 水平。Western blot 用于测定 MAPK1 蛋白表达。观察到前列腺肿瘤组织中 ARV7 和 U2AF1 之间存在负相关。U2AF1 的下调与前列腺癌患者的不良预后相关。U2AF1 与 ARV7 呈负相关,其下调促进了前列腺癌细胞增殖和比卡鲁胺耐药。U2AF1 对 ARV7 剪接的调控作用与 MAPK1 有关。U2AF1 通过调节 ARV7 剪接影响前列腺癌的增殖和抗雄激素耐药性。

相似文献

1
Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression.下调 U2AF1 促进 ARV7 剪接和前列腺癌进展。
Biochem Biophys Res Commun. 2021 Feb 19;541:56-62. doi: 10.1016/j.bbrc.2020.12.111. Epub 2021 Jan 19.
2
Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.原钙黏蛋白 B9 促进了对比卡鲁胺的耐药性,并与前列腺癌患者的生存有关。
Prostate. 2019 Feb;79(2):234-242. doi: 10.1002/pros.23728. Epub 2018 Oct 16.
3
Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.半乳糖凝集素-3通过调节前列腺癌中的雄激素受体信号传导参与肿瘤进展和抗雄激素药物耐药。
Anticancer Res. 2017 Jan;37(1):125-134. doi: 10.21873/anticanres.11297.
4
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.白细胞介素-6通过TIF2增加前列腺癌细胞对比卡鲁胺的抗性。
Mol Cancer Ther. 2009 Mar;8(3):665-71. doi: 10.1158/1535-7163.MCT-08-0823. Epub 2009 Feb 24.
5
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.抗雄激素阿帕鲁胺(ARN-509)与比卡鲁胺对前列腺癌细胞系雄激素受体通路影响的比较。
Anticancer Drugs. 2018 Apr;29(4):323-333. doi: 10.1097/CAD.0000000000000592.
6
Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.miR-212失调通过hnRNPH1介导的AR和AR-V7调控促进去势抵抗:对前列腺癌种族差异的影响
Clin Cancer Res. 2016 Apr 1;22(7):1744-56. doi: 10.1158/1078-0432.CCR-15-1606. Epub 2015 Nov 9.
7
The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.雄激素拮抗剂比卡鲁胺通过丝裂原活化蛋白激酶(MARK)通路在人前列腺癌 PC3 细胞中激活 741 密码子突变的雄激素受体(AR)。
Oncol Rep. 2010 Nov;24(5):1395-9. doi: 10.3892/or_00000998.
8
Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.姜黄素与比卡鲁胺联合使用通过SAPK/JNK和MEK/ERK1/2介导的靶向NF-κB/p65和MUC1-C增强了对雄激素非依赖性前列腺癌细胞的生长抑制作用。
J Exp Clin Cancer Res. 2015 May 15;34(1):46. doi: 10.1186/s13046-015-0168-z.
9
Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.雄激素受体及其剪接变异体 7 在转移性去势抵抗性前列腺癌患者外周血单个核细胞和循环肿瘤细胞中的表达。
Cells. 2020 Jan 14;9(1):203. doi: 10.3390/cells9010203.
10
Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.长期使用阿扎胞苷治疗会产生分化作用,使去势抵抗性前列腺癌细胞对比卡鲁胺敏感。
Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.

引用本文的文献

1
Revealing the role of U2AF1 in splicing regulation and chimeric RNA dynamics.揭示U2AF1在剪接调控和嵌合RNA动态变化中的作用。
Sci Rep. 2025 May 9;15(1):16235. doi: 10.1038/s41598-025-99865-1.
2
Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen.克服比卡鲁胺耐药性的最新进展:透视对新型抗雄激素药物的耐药性
ACS Pharmacol Transl Sci. 2024 Mar 7;7(4):905-914. doi: 10.1021/acsptsci.3c00299. eCollection 2024 Apr 12.
3
U2AF1 in various neoplastic diseases and relevant targeted therapies for malignant cancers with complex mutations (Review).
U2AF1 在各种肿瘤性疾病及相关复杂突变恶性肿瘤的靶向治疗中的作用(综述)。
Oncol Rep. 2024 Jan;51(1). doi: 10.3892/or.2023.8664. Epub 2023 Nov 17.
4
Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer.初治雄激素依赖性前列腺癌中雄激素受体(AR)及AR剪接变体(AR-SVs)表达的种族差异
Biomedicines. 2023 Feb 21;11(3):648. doi: 10.3390/biomedicines11030648.
5
Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain and Modulation via Direct Interactions with DNA Abasic Sites: Understanding the Mechanisms Involved in Castration-Resistant Prostate Cancer.雄激素受体 DNA 结合域的机制研究及其与 DNA 无碱基位点的直接相互作用的调节:理解去势抵抗性前列腺癌中涉及的机制。
Int J Mol Sci. 2023 Jan 9;24(2):1270. doi: 10.3390/ijms24021270.
6
Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.用半胱氨酸选择性不可逆共价抑制剂抑制雄激素受体剪接变异体治疗前列腺癌。
Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2211832120. doi: 10.1073/pnas.2211832120. Epub 2022 Dec 28.
7
Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.利用氟他胺和无雄激素环境建立 Lncap-AI 前列腺癌细胞系以促进细胞黏附。
BMC Mol Cell Biol. 2022 Nov 28;23(1):51. doi: 10.1186/s12860-022-00453-2.
8
Powerful p-value combination methods to detect incomplete association.强大的 p 值组合方法,用于检测不完全关联。
Sci Rep. 2021 Mar 26;11(1):6980. doi: 10.1038/s41598-021-86465-y.